The benefits and risks of PrEP and kidney function. by Mocroft, A & Ryom, L
The benefits and risks of PrEP and kidney function 
(title < 60 characters including spaces) 
Amanda Mocroft1, Lene Ryom2 
1Dept Infection and Population Health, University College London, London, UK.  2Dept. of Infectious 
diseases, CHIP, University of Copenhagen, Denmark. 
 
In the recent Lancet HIV report from Gandhi et al (ref), a modest decrease in renal function as 
estimated by creatinine clearance (CrCl) in persons starting Pre-exposure prophylaxis for HIV (PrEP) 
was reported.  There was a higher decline in those aged >40 or with CrCl<90.   Further, the rate of 
decline was strongly associated with concentration of tenofovir in hair samples.     
The clear and substantial benefit of PrEP has been shown in a number of studies1-3, with estimates of 
approximately 80% reductions in HIV-infections among those using PrEP3.  Tenofovir disoproxil 
fumarate (TDF) and emtricitabine are currently the only recommended combination due to lack of 
data on other combinations4.  Evidence on the use of tenofovir-alafenamide (TAF) as part of PrEP is 
currently limited, but results from HIV-positive persons suggest a more favourable renal profile16, 
which may make it an alternative for those at highest risk of renal disease.  TDF has been reported to 
be associated with renal toxicities in HIV-positive persons enrolled in cohort studies, with increasing 
risk of chronic kidney disease as exposure to TDF increases5-7.  This result was not evident in clinical 
trials demonstrating clinical efficacy of TDF in HIV-positive persons, many of which demonstrated an 
initial decline in estimated glomerular filtration rate associated with TDF limited to the first few 
months of treatment8;9.  The long term relationship between TDF and chronic kidney disease has 
only become evident when large heterogeneous cohorts of HIV-positive persons have been followed 
for many years.    
There are a number of important caveats to note with the important results from Gandhi et al (ref).  
The persons included were from iPrEx open label extension of 3 clinical trials.  As the authors note, 
persons included in clinical trials tend to be less representative of a ‘normal’ population10;11, and 
typically have less underlying comorbidities, such as diabetes, hypertension, hepatitis C coinfection 
or other risk factors which would place them at a higher risk of renal disease12;13.   As such, although 
the changes in renal function are small, they may be larger when PrEP is rolled out to a more 
heterogeneous population.  Balanced against this is the fact that although statistically significant 
decreases in CrCl were observed, whether these are clinically relevant and the extent to which they 
are reversible in all groups or only in those at lowest risk of chronic kidney disease when PrEP is 
stopped remain to be seen.  Early evidence would suggest that the majority of persons with a 
decrease in CrCl<60 recover their renal function on stopping PrEP14;15, but as yet, this is a small group 
of individuals and further data is needed, as well as many years of follow-up to understand the long 
term clinical consequences of the changes in a laboratory based parameter. 
One simple way to assess the risk and benefit of treatment is the number needed to benefit or harm.  
Data from Molina et al3 suggest the number needed to treat to benefit (no HIV-infection) was 18, 
and the number needed to treat to harm (grade 2+ proteinuria) was 143.  Although the benefit 
clearly outweighs the harm, it is worth emphasising that the number needed to treat to harm will be 
significantly lower in those aged > 40, or with poorer renal function at starting PrEP, as illustrated by 
Gandhi et al (ref), where the chance of a single CrCl < 70 was significantly higher.  Clearly other 
measures of harm which are clinically relevant are needed in this population, as well as the mean to 
identify those at greatest risk of harm with long term exposure to PrEP. 
TDF-based PrEP can clearly benefit the majority of people who are treated. The study from Gandhi et 
al (ref) illustrates the importance of administering PrEP in a setting with access to regular clinical 
follow-up, including monitoring of renal function, until further data is available.   There is an ongoing 
need to understand the risk of declining renal function in persons using PrEP with underlying 
comorbidities and higher risk of renal problems, as well as the extent to which these resolve when 
PrEP is stopped.  This requires long term follow-up of persons exposed to PrEP, as well as exposure 
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